Free tool
Drug Trial Radar: Dermatology
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
223
Completed, industry sponsors, Dermatology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed223
223 trials
Showing 1 to 25, recently updated first.
- A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)Pivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT05620836 · 619 participants · Start Feb 22, 2023 · Primary completion Jan 7, 2025
Drug: Povorcitinib; Placebo · For: Hidradenitis Suppurativa (HS)
Sites: Scottsdale, Arizona; Arkansas City, Arkansas; Fayetteville, Arkansas · 101 sites in all
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
NCT04242446 · 505 participants · Start Feb 19, 2020 · Primary completion Apr 7, 2022
Drug: Bimekizumab · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 88 sites in all
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
NCT04242498 · 509 participants · Start Mar 2, 2020 · Primary completion Nov 9, 2021
Drug: Bimekizumab · For: Hidradenitis Suppurativa
Sites: Fountain Valley, California; Thousand Oaks, California; Miami, Florida · 91 sites in all
- Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Participants With Acne VulgarisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT03664752 · 585 participants · Start Dec 10, 2018 · Primary completion May 7, 2020
Drug: IDP-120 Gel; IDP-120 Vehicle Gel · For: Acne Vulgaris
Sites: Rogers, Arkansas; Manhattan Beach, California; San Diego, California · 20 sites in all
- Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne VulgarisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02932306 · 820 participants · Start Nov 3, 2015 · Primary completion Feb 22, 2017
Drug: IDP-121 Lotion; IDP-121 Vehicle Lotion · For: Acne
Sites: Guntersville, Alabama; Phoenix, Arizona; Hot Springs, Arkansas · 39 sites in all
- A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
NCT04901195 · 658 participants · Start May 27, 2021 · Primary completion Jul 22, 2026
Drug: Bimekizumab · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Phoenix, Arizona; Fountain Valley, California · 145 sites in all
- Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis SuppurativaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04179175 · 702 participants · Start Mar 18, 2020 · Primary completion May 26, 2023
Drug: secukinumab; secukinumab · For: Hidradenitis Suppurativa
Sites: Rogers, Arkansas; San Diego, California; Whittier, California · 191 sites in all
- A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic KeratosisPivotal-lookingCompleted
Almirall, S.A.Industry
NCT06135415 · 280 participants · Start Dec 21, 2023 · Primary completion Apr 30, 2025
Drug: Tirbanibulin · For: Keratosis, Actinic
Sites: Augsburg, Germany; Bad Bentheim, Germany; Bochum, Germany · 35 sites in all
- The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI IchthyosisPivotal-lookingCompleted
LEO PharmaIndustry
NCT05295732 · 153 participants · Start Jun 21, 2022 · Primary completion Jun 17, 2024
Drug: TMB-001; Matching Vehicle · For: Ichthyosis
Sites: Phoenix, Arizona; Palo Alto, California; Centennial, Colorado · 35 sites in all
- A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT05620823 · 608 participants · Start Dec 19, 2022 · Primary completion Feb 3, 2025
Drug: Povorcitinib; Placebo · For: Hidradenitis Suppurativa (HS)
Sites: Phoenix, Arizona; Arkansas City, Arkansas; Fort Smith, Arkansas · 104 sites in all
- A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne VulgarisPivotal-lookingCompleted
Ascletis Pharmaceuticals Co., Ltd.Industry
NCT06248008 · 240 participants · Start Apr 18, 2024 · Primary completion Nov 12, 2025
Drug: ASC40 · For: Acne
Sites: Shanghai, China
- DMT310-009 Topical in the Treatment of Acne VulgarisPivotal-lookingCompleted
Dermata TherapeuticsIndustry
NCT06090721 · 520 participants · Start Dec 8, 2023 · Primary completion Mar 31, 2025
Drug: DMT310; Placebo · For: Acne Vulgaris
Sites: Freemont, California; Austin, Texas
- A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne VulgarisPivotal-lookingCompleted
Ascletis Pharmaceuticals Co., Ltd.Industry
NCT06192264 · 480 participants · Start Jan 23, 2024 · Primary completion May 19, 2025
Drug: ASC40 · For: Acne
Sites: Bengbu, China; Hefei, China; Wuhu, China · 41 sites in all
- Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-upPivotal-lookingCompleted
LEO PharmaIndustry
NCT02549352 · 391 participants · Start Nov 2015 · Primary completion Sep 22, 2016
Drug: LEO43204 gel; Vehicle gel · For: Actinic Keratosis
Sites: Recklinghausen, Germany
- Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-upPivotal-lookingCompleted
LEO PharmaIndustry
NCT02547363 · 373 participants · Start Nov 2015 · Primary completion Aug 17, 2016
Drug: LEO 43204 gel; Vehicle gel · For: Actinic Keratosis
Sites: Smithtown, New York
- Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and ScalpPivotal-lookingCompleted
LEO PharmaIndustry
NCT01600014 · 463 participants · Start May 2012 · Primary completion Feb 2014
Drug: Ingenol mebutate gel, 0.015%; Vehicle gel · For: Actinic Keratosis
Sites: Subiaco, Australia; Edmonton, Canada; Vancouver, Canada · 13 sites in all
- Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-upPivotal-lookingCompleted
LEO PharmaIndustry
NCT02547233 · 437 participants · Start Nov 2015 · Primary completion Nov 2016
Drug: LEO 43204 gel; Vehicle gel · For: Actinic Keratosis
Sites: Arlington Heights, Illinois
- A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and ScalpPivotal-lookingCompleted
LEO PharmaIndustry
NCT01541553 · 367 participants · Start Mar 2012 · Primary completion Jul 2013
Drug: Vehicle; Ingenol metabute · For: Actinic Keratosis
Sites: Fremont, California; Oceanside, California; San Diego, California · 35 sites in all
- Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-upPivotal-lookingCompleted
LEO PharmaIndustry
NCT02549339 · 383 participants · Start Nov 13, 2015 · Primary completion Aug 5, 2016
Drug: LEO 43204 gel; Vehicle gel · For: Actinic Keratosis
Sites: Carmel, Indiana
- Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or ChestPivotal-lookingCompleted
LEO PharmaIndustry
NCT02361216 · 729 participants · Start Apr 2015 · Primary completion Mar 2016
Drug: Ingenol Mebutate · For: Actinic Keratosis
Sites: Carmel, Indiana
- A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/ExtremitiesPivotal-lookingCompleted
LEO PharmaIndustry
NCT01787383 · 200 participants · Start Feb 2013 · Primary completion Jan 2014
Drug: Ingenol mebutate gel 0.05 %; Ingenol mebutate gel 0.015 % · For: Actinic Keratosis
Sites: Modena, Italy
- A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.Pivotal-lookingCompleted
Journey Medical CorporationIndustry
NCT05296629 · 323 participants · Start Mar 14, 2022 · Primary completion Jun 30, 2023
Drug: DFD-29; Doxycycline and 1 more · For: Papulopustular Rosacea
Sites: Rogers, Arkansas; Cerritos, California; Fremont, California · 27 sites in all
- A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)Pivotal-lookingCompleted
Journey Medical CorporationIndustry
NCT05343455 · 330 participants · Start Mar 29, 2022 · Primary completion Jun 30, 2023
Drug: DFD-29; Doxycycline and 1 more · For: Papulopustular Rosacea
Sites: Santa Monica, California; Doral, Florida; Miami, Florida · 24 sites in all
- Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03713632 · 545 participants · Start Feb 25, 2019 · Primary completion Sep 23, 2021
Drug: Secukinumab; Placebo · For: Hidradenitis Suppurativa
Sites: San Diego, California; Whittier, California; Coral Gables, Florida · 108 sites in all
- This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03713619 · 544 participants · Start Jan 31, 2019 · Primary completion Oct 1, 2021
Drug: secukinumab; Placebo · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Rogers, Arkansas; Anaheim, California · 111 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.